BU
ALXN

BBVA USA’s Alexion Pharmaceuticals ALXN Stock Holding History

BBVA USA’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-667
Closed -$123K – 1042
2021
Q2 		$123K Buy
+667
New +$114K 0.01% 533

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

BBVA USA's ALXN Position: Q3 2021 in Review

BBVA USA sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 667 shares — an estimated $123K sold.

BBVA USA first reported a position in ALXN in Q2 2021 and held it in 1 quarter. The position peaked at $123K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • BBVA USA reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • BBVA USA sold 667 Alexion Pharmaceuticals shares in Q3 2021, an estimated $123K.
  • BBVA USA first reported a position in Alexion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • BBVA USA's Alexion Pharmaceuticals position peaked at $123K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.